RKLB Fundamental Analysis - ROCKET LAB CORP

Name: ROCKET LAB CORP (RKLB) Stock
Brand: ROCKET LAB CORP
Rating: 5.5 (3 reviews)

Fundamental Rating

Overall RKLB gets a fundamental rating of 3 out of 10. We evaluated RKLB against 72 industry peers in the Aerospace & Defense industry. The financial health of RKLB is average, but there are quite some concerns on its profitability. RKLB shows excellent growth, but is valued quite expensive already.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year RKLB has reported negative net income.

In the past year RKLB has reported a negative cash flow from operations.

In the past 5 years RKLB always reported negative net income.

In the past 5 years RKLB always reported negative operating cash flow.

1.2 Ratios

RKLB has a worse Return On Assets (-14.89%) than 72.22% of its industry peers.

RKLB's Return On Equity of -33.60% is on the low side compared to the rest of the industry. RKLB is outperformed by 72.22% of its industry peers.

		Industry Rank	Sector Rank
ROA	-14.89%
ROE	-33.6%
ROIC	N/A

ROA(3y)-16.4%

ROA(5y)-18.08%

ROE(3y)-34.28%

ROE(5y)-34.08%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

With a decent Gross Margin value of 29.04%, RKLB is doing good in the industry, outperforming 66.67% of the companies in the same industry.

RKLB does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	29.04%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

RKLB does not have a ROIC to compare to the WACC, probably because it is not profitable.

RKLB has more shares outstanding than it did 1 year ago.

Compared to 5 years ago, RKLB has more shares outstanding

The debt/assets ratio for RKLB is higher compared to a year ago.

2.2 Solvency

An Altman-Z score of 16.27 indicates that RKLB is not in any danger for bankruptcy at the moment.

The Altman-Z score of RKLB (16.27) is better than 94.44% of its industry peers.

RKLB has a Debt/Equity ratio of 0.60. This is a neutral value indicating RKLB is somewhat dependend on debt financing.

With a Debt to Equity ratio value of 0.60, RKLB is not doing good in the industry: 61.11% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
Debt/Equity	0.6
Debt/FCF	N/A
Altman-Z	16.27

ROIC/WACCN/A

WACC9.79%

2.3 Liquidity

A Current Ratio of 2.67 indicates that RKLB has no problem at all paying its short term obligations.

RKLB's Current ratio of 2.67 is in line compared to the rest of the industry. RKLB outperforms 58.33% of its industry peers.

A Quick Ratio of 2.33 indicates that RKLB has no problem at all paying its short term obligations.

With a decent Quick ratio value of 2.33, RKLB is doing good in the industry, outperforming 76.39% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	2.67
Quick Ratio	2.33

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 8.11% over the past year.

The Revenue has grown by 78.34% in the past year. This is a very strong growth!

RKLB shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 55.23% yearly.

EPS 1Y (TTM)8.11%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%110%

Revenue 1Y (TTM)78.34%

Revenue growth 3Y91.41%

Revenue growth 5Y55.23%

Sales Q2Q%47.97%

3.2 Future

The Earnings Per Share is expected to grow by 32.40% on average over the next years. This is a very strong growth

Based on estimates for the next years, RKLB will show a very strong growth in Revenue. The Revenue will grow by 31.95% on average per year.

EPS Next Y-19.95%

EPS Next 2Y24.45%

EPS Next 3Y30.19%

EPS Next 5Y32.4%

Revenue Next Year35.91%

Revenue Next 2Y44.34%

Revenue Next 3Y40.17%

Revenue Next 5Y31.95%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RKLB. In the last year negative earnings were reported.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RKLB. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as RKLB's earnings are expected to grow with 30.19% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y24.45%

EPS Next 3Y30.19%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

RKLB does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

ROCKET LAB CORP

NASDAQ:RKLB (11/13/2025, 6:50:09 PM)

After market: 45.65 +0.4 (+0.88%)

45.25

-4.72 (-9.45%)

Chartmill FA Rating

GICS SectorIndustrials

GICS IndustryGroupCapital Goods

GICS IndustryAerospace & Defense

Earnings (Last)11-10 2025-11-10/amc

Earnings (Next)N/A N/A

Inst Owners61.26%

Inst Owner Change3.08%

Ins Owners0.64%

Ins Owner Change9.26%

Market Cap21.90B

Revenue(TTM)436.21M

Net Income(TTM)-231.31M

Analysts80

Price Target59.09 (30.59%)

Short Float %11.54%

Short Ratio2.3

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)1

Avg EPS beat(2)-1.65%

Min EPS beat(2)-11.38%

Max EPS beat(2)8.09%

EPS beat(4)3

Avg EPS beat(4)3.2%

Min EPS beat(4)-11.38%

Max EPS beat(4)12.21%

EPS beat(8)7

Avg EPS beat(8)8.2%

EPS beat(12)8

Avg EPS beat(12)4.25%

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)1

Avg Revenue beat(2)1.82%

Min Revenue beat(2)-0.99%

Max Revenue beat(2)4.63%

Revenue beat(4)2

Avg Revenue beat(4)0.87%

Min Revenue beat(4)-0.99%

Max Revenue beat(4)4.63%

Revenue beat(8)2

Avg Revenue beat(8)-1.29%

Revenue beat(12)5

Avg Revenue beat(12)-0.34%

Revenue beat(16)8

Avg Revenue beat(16)1.42%

PT rev (1m)23.45%

PT rev (3m)56.4%

EPS NQ rev (1m)-0.18%

EPS NQ rev (3m)-5.84%

EPS NY rev (1m)-0.28%

EPS NY rev (3m)-8.37%

Revenue NQ rev (1m)0.29%

Revenue NQ rev (3m)0.94%

Revenue NY rev (1m)0.56%

Revenue NY rev (3m)2.41%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	43.43
P/FCF	N/A
P/OCF	N/A
P/B	31.81
P/tB	38.86
EV/EBITDA	N/A

EPS(TTM)-0.34

EYN/A

EPS(NY)-0.17

Fwd EYN/A

FCF(TTM)-0.42

FCFYN/A

OCF(TTM)-0.23

OCFYN/A

SpS1.04

BVpS1.42

TBVpS1.16

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-14.89%
ROE	-33.6%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	29.04%
FCFM	N/A

ROA(3y)-16.4%

ROA(5y)-18.08%

ROE(3y)-34.28%

ROE(5y)-34.08%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score4

Asset Turnover0.32

Health

		Industry Rank	Sector Rank
Debt/Equity	0.6
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	268.86%
Cap/Sales	18.5%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	2.67
Quick Ratio	2.33
Altman-Z	16.27

F-Score4

WACC9.79%

ROIC/WACCN/A

Cap/Depr(3y)174.96%

Cap/Depr(5y)206.2%

Cap/Sales(3y)19.28%

Cap/Sales(5y)34.12%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)8.11%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%110%

EPS Next Y-19.95%

EPS Next 2Y24.45%

EPS Next 3Y30.19%

EPS Next 5Y32.4%

Revenue 1Y (TTM)78.34%

Revenue growth 3Y91.41%

Revenue growth 5Y55.23%

Sales Q2Q%47.97%

Revenue Next Year35.91%

Revenue Next 2Y44.34%

Revenue Next 3Y40.17%

Revenue Next 5Y31.95%

EBIT growth 1Y-28.41%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year51.27%

EBIT Next 3Y41.55%

EBIT Next 5Y31.86%

FCF growth 1Y-70.08%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-50.93%

OCF growth 3YN/A

OCF growth 5YN/A

ROCKET LAB CORP / RKLB FAQ

Can you provide the ChartMill fundamental rating for ROCKET LAB CORP?

ChartMill assigns a fundamental rating of 3 / 10 to RKLB.

Can you provide the valuation status for ROCKET LAB CORP?

ChartMill assigns a valuation rating of 1 / 10 to ROCKET LAB CORP (RKLB). This can be considered as Overvalued.

How profitable is ROCKET LAB CORP (RKLB) stock?

ROCKET LAB CORP (RKLB) has a profitability rating of 1 / 10.

What is the expected EPS growth for ROCKET LAB CORP (RKLB) stock?

The Earnings per Share (EPS) of ROCKET LAB CORP (RKLB) is expected to decline by -19.95% in the next year.

ROCKET LAB CORP (RKLB) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

ROCKET LAB CORP / RKLB FAQ

Can you provide the ChartMill fundamental rating for ROCKET LAB CORP?

Can you provide the valuation status for ROCKET LAB CORP?

How profitable is ROCKET LAB CORP (RKLB) stock?

What is the expected EPS growth for ROCKET LAB CORP (RKLB) stock?